Tilray Inc (NASDAQ:TLRY) Director Christine St.Clare sold 4,000 shares of the stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $50.01, for a total value of $200,040.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
NASDAQ:TLRY opened at $47.20 on Thursday. The company has a quick ratio of 2.06, a current ratio of 2.35 and a debt-to-equity ratio of 1.13. The stock has a fifty day moving average price of $43.43. Tilray Inc has a 1 year low of $20.10 and a 1 year high of $300.00. The stock has a market capitalization of $4.62 billion and a P/E ratio of -57.56.
Tilray (NASDAQ:TLRY) last released its earnings results on Tuesday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.02). Tilray had a negative return on equity of 43.71% and a negative net margin of 159.09%. The firm had revenue of $23.00 million during the quarter, compared to analysts’ expectations of $20.50 million. Tilray’s quarterly revenue was up 194.9% compared to the same quarter last year. Analysts forecast that Tilray Inc will post -0.89 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in the business. Zevenbergen Capital Investments LLC increased its position in Tilray by 37.1% in the first quarter. Zevenbergen Capital Investments LLC now owns 730,280 shares of the company’s stock worth $47,848,000 after buying an additional 197,540 shares during the last quarter. Hellman Jordan Management Co. Inc. MA purchased a new stake in Tilray in the first quarter worth $3,276,000. Stevens Capital Management LP purchased a new stake in Tilray in the first quarter worth $2,106,000. Park West Asset Management LLC purchased a new stake in Tilray in the fourth quarter worth $2,244,000. Finally, D. E. Shaw & Co. Inc. purchased a new stake in Tilray in the fourth quarter worth $2,119,000. 2.10% of the stock is owned by institutional investors and hedge funds.
TLRY has been the subject of a number of research analyst reports. Jefferies Financial Group initiated coverage on Tilray in a research report on Friday, March 8th. They set an “underperform” rating and a $61.00 price target for the company. Piper Jaffray Companies set a $90.00 price target on Tilray and gave the company a “buy” rating in a research report on Tuesday, March 19th. Roth Capital reaffirmed a “hold” rating on shares of Tilray in a research report on Thursday, March 21st. Vertical Research initiated coverage on Tilray in a research report on Friday, April 12th. They set a “sell” rating for the company. Finally, Vertical Group initiated coverage on Tilray in a research report on Friday, April 12th. They set a “sell” rating for the company. Three analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $79.27.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Read More: CD Ladder
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.